Olaparib
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer, Breast Cancer
Trial Timeline
May 25, 2020 → Sep 30, 2022
NCT ID
NCT04330040About Olaparib
Olaparib is a approved stage product being developed by AstraZeneca for Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04330040. Target conditions include Ovarian Cancer, Breast Cancer.
What happened to similar drugs?
10 of 20 similar drugs in Ovarian Cancer were approved
Approved (10) Terminated (4) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03063710 | Pre-clinical | Completed |
| NCT05501548 | Phase 2 | Terminated |
| NCT04951492 | Phase 2 | Terminated |
| NCT05482074 | Phase 2 | Withdrawn |
| NCT05262608 | Phase 2 | UNKNOWN |
| NCT04884360 | Phase 3 | Active |
| NCT04515836 | Phase 2 | Recruiting |
| NCT04532645 | Pre-clinical | Completed |
| NCT04421963 | Phase 3 | Active |
| NCT04330040 | Approved | Completed |
| NCT04236414 | Phase 1 | Completed |
| NCT03782818 | Phase 1/2 | Terminated |
| NCT03829345 | Phase 2 | UNKNOWN |
| NCT03786796 | Phase 2 | Recruiting |
| NCT03955640 | Phase 1 | Terminated |
| NCT03742895 | Phase 2 | Active |
| NCT04152941 | Pre-clinical | Completed |
| NCT03570476 | Phase 2 | Terminated |
| NCT03470805 | Phase 2 | Completed |
| NCT03448718 | Phase 2 | Completed |
Competing Products
20 competing products in Ovarian Cancer